TWD 179.0
(-1.65%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 1.08 Billion TWD | -23.44% |
2022 | 1.41 Billion TWD | 17.25% |
2021 | 1.2 Billion TWD | 37.74% |
2020 | 876.55 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 1.11 Billion TWD | 2.98% |
2024 Q2 | 1.06 Billion TWD | -4.59% |
2023 Q4 | 1.08 Billion TWD | -6.7% |
2023 FY | 1.08 Billion TWD | -23.44% |
2023 Q1 | 1.19 Billion TWD | -12.97% |
2023 Q3 | 1.16 Billion TWD | 2.57% |
2023 Q2 | 1.13 Billion TWD | -5.09% |
2022 Q4 | 1.37 Billion TWD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 605.96 Million TWD | -78.852% |
Maxigen Biotech Inc. | 50 Thousand TWD | -2167454.0% |
SciVision Biotech Inc. | 347.91 Million TWD | -211.508% |
Bionime Corporation | 2.81 Billion TWD | 61.53% |
Pegavision Corporation | 1.56 Billion TWD | 30.706% |